Rocbrutinib
Based on 1 Customer Validation
Rocbrutinib is an orally available, highly selective Bruton's tyrosine kinase (BTK) inhibitor, with an IC50 of 0.11 nM against wild-type BTK and an IC50 of 1.0 nM against C481S-mutated BTK. Rocbrutinib reduces the viability of leukemia cells, induces cytotoxicity and inhibits cell migration. Rocbrutinib can be used in research related to chronic lymphocytic leukemia, non-Hodgkin's lymphoma and mantle cell lymphoma.
For research use only. We do not sell to patients.
- Purity : 99.76%
- CAS No.: 2485861-07-0
- Formula: C42H51N9O5
- Molecular Weight:761.91
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
All EGFR Isoforms
More
Biological Activity
Description
In Vitro
Rocbrutinib (LP-168) is a highly selective BTK inhibitor with nanomolar enzymatic potency against both wild-type and BTKC481S[1].
Rocbrutinib (LP-168) (increasing concentrations; 2 hours) inhibits BCR signaling in primary CLL B cells, reducing phosphorylation of BTK and PLCγ2 significantly[1].
Rocbrutinib (LP-168) (2 hours) reduces the migration capacity of primary CLL B cells towards CXCL12 and CXCL14 by over 50%[1].
Rocbrutinib (LP-168) (48 hours) induces dose-dependent cytotoxicity in primary CLL B cells, both in the absence and presence of HS-5 stromal cell support[1].
Rocbrutinib (LP-168) reduces CCL3 and CCL4 chemokine production by primary CLL B cells by 93% each[1].
Rocbrutinib (LP-168) (1 μM) induces modest cytotoxicity and marked reduction of CCL3 and CCL4 production in TMD8 cells expressing BTKT474I[1].
Rocbrutinib (LP-168) induces cytotoxicity and marked reduction of CCL3 and CCL4 production in TMD8 cells expressing BTKC481S[1].
Rocbrutinib forms a covalent bond to BTK's C481 residue and engages in hydrogen bonding with M477, D539, and K430 within the ATP-binding site[2].
Rocbrutinib binds WT BTK (IC50 = 4.7 nM), C481S BTK (IC50 = 49.7 nM), T474I BTK (IC50 = 13.1 nM), and L528W BTK (IC50 = 80.4 nM) with low nanomolar affinity in a NanoBRET assay[2].
Rocbrutinib exhibits nanomolar binding potency to full-length WT BTK and BTK with BTKC481S, BTKV416L, BTKM437R, or BTKL528W mutations in HEK293T cells in an FPCBA[2].
Rocbrutinib inhibits viability of TMD8 cells expressing WT, C481S, T474I, or L528W BTK with nanomolar GI50 potency[2].
Rocbrutinib potently inhibits BCR signaling in TMD8 cells expressing WT, C481S, T474I, or L528W BTK, reducing CCL3/CCL4 cytokine production by >96% and blocking phosphorylation of BTK, PLCγ2, ERK, and AKT[2].
Rocbrutinib (500 nM; 2 hours) inhibits BCR signaling in primary CLL B-cells (including those with BTKC481S), reducing phosphorylation of BTK by 98.9%, PLCγ2 by 85.6%, ERK by 59.3%, and AKT by 68.9%[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
Rocbrutinib (50 mg/kg; p.o.; daily) significantly improves median survival to 122 days in Eμ-MTCP1 chronic lymphocytic leukemia engrafted mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Eμ-TCL1 (engrafted with chronic lymphocytic leukemia)[2]
-
Dosage:50 mg/kg
-
Administration:p.o.; daily
-
Result:Extended median survival to 51 days, which was significantly improved relative to vehicle and ibrutinib controls.
-
Animal Model:Eμ-MTCP1 (engrafted with chronic lymphocytic leukemia)[2]
-
Dosage:50 mg/kg
-
Administration:p.o.; daily
-
Result:Extended median survival to 122 days, which was significantly improved relative to vehicle and ibrutinib controls.
Chemical Information
-
CAS No. 2485861-07-0
-
Appearance Solid
-
Molecular Weight 761.91
-
Formula C42H51N9O5
-
Color White to light yellow
-
SMILES
O=C1C2=CC(CC(C)(C3)C)=C3N2CCN1C4=C(C(C(N=C5NC6=CC(NC(C=C)=O)=C(N7[C@H](CN(C8CCOCC8)CC7)C)C=C6)=CN(C)C5=O)=CC=N4)CO
-
Synonyms
LP-168
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 125 mg/mL (164.06 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Scratch/Wound-Healing Migration Assay
The scratch/wound-healing migration assay measures collective migration of adherent cells into an experimentally created cell-free gap in a confluent monolayer. The readout is generated by imaging the gap immediately after scratching and at later time points, then quantifying reduction in wound area, wound width, or percentage closure as cells move into the denuded region. Gap closure reflects cell migration but may also include cell proliferation, so interpretation should distinguish migration-focused conditions from proliferation-driven closure when possible, such as by using short assay windows, serum-controlled conditions, cell counting, or proliferation controls reported in published protocols.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Cell migration
Cell migration is a method that plays an important role in wound healing, cell differentiation, embryonic development, etc.
-
Chemotaxis Gradient Chamber Assay 1
The chemotaxis gradient chamber assay is based on the principle of observing directional cell migration in response to a stable, linear or quasi-linear concentration gradient of a chemoattractant formed between two fluid reservoirs separated by a narrow observation chamber. Cells placed within the chamber respond to the gradient by polarized movement toward higher chemoattractant concentrations, allowing quantification of chemotactic behavior in real time under microscopy. The classic Zigmond chamber design enables simultaneous visualization of gradient formation and individual cell trajectories, making it suitable for studying leukocyte chemotaxis and other motile cell types in vitro.
-
Under-Agarose Cell Migration Assay
The under-agarose cell migration assay is a classical in vitro chemotaxis method designed to evaluate directed cell movement through a semi-solid agarose matrix toward soluble chemoattractant gradients, enabling visualization and quantification of leukocyte or motile cell migration in a confined 2D-like environment. In this system, cells and chemoattractants are placed in separate wells cut into an agarose gel, allowing diffusion-driven gradient formation that guides directional migration, which is typically assessed by measuring migration distance, cell morphology changes, and accumulation toward the chemoattractant source. This assay has been widely used to study neutrophil and leukocyte chemotaxis as a simple alternative to filter-based migration systems and allows direct microscopic observation of migrating cells under near-physiological confinement conditions.
-
Neural Crest/Neuronal Cell Migration Explant Assay
Neural crest (NC) and neuronal cell migration explant assays are in vitro systems in which neural tube-derived tissues are cultured to allow premigratory or newly emigrated neural crest cells to undergo epithelial-to-mesenchymal transition (EMT), migrate away from the explant, and form a measurable radial outgrowth that reflects migratory capacity and environmental responsiveness. These assays typically quantify migration by measuring the expansion of cell outgrowth from neural tube or neural plate border explants over time, often comparing early and later timepoints to derive a migration index such as a radius ratio, which reflects net cell dispersal from the explant core. Neural tube explant cultures preserve key aspects of neural crest behavior, including EMT, migration, and early differentiation, making them suitable for assessing intrinsic migratory ability and extrinsic cue dependence. However, studies emphasize that migratory outgrowth from neural tube explants may include non-n
-
Transwell/Boyden Chamber Migration Assay
The Transwell/Boyden chamber migration assay measures cell movement through a porous membrane separating an upper and lower chamber, usually after a chemoattractant gradient is established by placing cells in the upper chamber and chemoattractant-containing medium in the lower chamber. The readout is generated by quantifying cells that traverse the membrane and appear on the lower membrane surface or in the lower chamber, depending on whether the cell type is adherent or non-adherent. This assay reflects chemotactic or haptotactic migration rather than matrix invasion unless an extracellular-matrix barrier is added to the membrane.
-
3D Collagen/Hydrogel Matrix Migration Assay
The 3D collagen/hydrogel matrix migration assay is based on embedding cells within or on top of a fibrillar collagen type I-rich three-dimensional matrix to model in vivo-like extracellular matrix (ECM) architecture, enabling analysis of cell migration through a physically and biochemically relevant scaffold. In contrast to 2D migration systems, cells in 3D matrices interact with fibrillar collagen networks, requiring coordinated adhesion remodeling and proteolytic or non-proteolytic deformation mechanisms to move through confined spaces, thereby providing a more physiologically relevant readout of invasive and migratory behavior in tissue-like environments. Cell movement in 3D collagen matrices is typically quantified by tracking single-cell trajectories, invasion depth, or matrix penetration over time, reflecting combined effects of cytoskeletal dynamics, cell-ECM adhesion turnover, and ECM remodeling. These systems are widely used to study tumor cell invasion and stromal cell motili
-
Cell-Exclusion Zone Migration Assay
The Cell-Exclusion Zone (CEZ) migration assay is an in vitro 2D cell migration method in which a defined cell-free area is created using removable physical barriers such as silicone stoppers, allowing cells to be seeded around the barrier and subsequently migrate into the cleared zone after barrier removal. This approach enables quantification of collective cell migration by monitoring repopulation of the initially cell-free region over time using microscopy-based imaging. Compared with scratch-based wound healing assays, barrier-based exclusion methods are designed to avoid mechanical damage to the extracellular matrix and reduce injury-induced effects on boundary cells, thereby improving interpretability of migration behavior in vitro. The assay readout is typically the progressive reduction in the cell-free area or the number of cells invading the exclusion zone, reflecting coordinated cell motility relevant to physiological processes such as wound healing, epithelial repair, and ca
-
Chemotaxis Gradient Chamber Assay 2
Chemotaxis gradient chamber assays measure directional cell migration in response to a soluble chemical gradient by imaging cells as they move across a defined observation region; the readout is generated from time-lapse cell trajectories, displacement toward the gradient, forward migration index, trajectory plots, rose/polar plots, and statistical tests of non-random directionality. The Dunn chamber is a direct-viewing glass chamber in which cells migrate across a bridge between control and chemoattractant wells, allowing observation of cells in a linear concentration gradient; related direct-viewing formats include the Insall chamber, which supports defined unidirectional gradients and high numerical-aperture microscopy, and the μ-Slide Chemotaxis chamber, which supports long-term live-cell imaging and gradient characterization with fluorescent dye.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.3125 mL | 6.5625 mL | 13.1249 mL | 32.8123 mL |
| 5 mM | 0.2625 mL | 1.3125 mL | 2.6250 mL | 6.5625 mL | |
| 10 mM | 0.1312 mL | 0.6562 mL | 1.3125 mL | 3.2812 mL | |
| 15 mM | 0.0875 mL | 0.4375 mL | 0.8750 mL | 2.1875 mL | |
| 20 mM | 0.0656 mL | 0.3281 mL | 0.6562 mL | 1.6406 mL | |
| 25 mM | 0.0525 mL | 0.2625 mL | 0.5250 mL | 1.3125 mL | |
| 30 mM | 0.0437 mL | 0.2187 mL | 0.4375 mL | 1.0937 mL | |
| 40 mM | 0.0328 mL | 0.1641 mL | 0.3281 mL | 0.8203 mL | |
| 50 mM | 0.0262 mL | 0.1312 mL | 0.2625 mL | 0.6562 mL | |
| 60 mM | 0.0219 mL | 0.1094 mL | 0.2187 mL | 0.5469 mL | |
| 80 mM | 0.0164 mL | 0.0820 mL | 0.1641 mL | 0.4102 mL | |
| 100 mM | 0.0131 mL | 0.0656 mL | 0.1312 mL | 0.3281 mL |